Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 17NIH 4INDUSTRY 4OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 9Sarcoma 1

Conditions

Sarcoma, Kaposi 1HIV Infections 1Castleman Disease 1

Interventions

Doxorubicin 3High-Throughput Nucleotide Sequencing 2Base Sequence 2trametinib 1spartalizumab 1ribociclib 1pembrolizumab 1palbociclib 1olaparib 1nilotinib 1ipatasertib 1glasdegib 1futibatinib 1durvalumab 1dactolisib 1dabrafenib 1ceritinib 1capmatinib 1camrelizumab 1apatinib 1anlotinib 1Zoledronic Acid 1Valganciclovir 1Transplantation, Homologous 1Transplantation, Autologous 1Rituximab 1Radiotherapy 1Psychoanalysis 1Nivolumab 1Lapatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Rituximab × Sarcoma × Clear all
NCT00127569 2007-01-12

Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy

French National Agency for Research on AIDS and Viral Hepatitis

Phase 2 Terminated
25 enrolled
LymphoidSarcoma

Castleman Disease, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡